162 related articles for article (PubMed ID: 8224241)
41. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography.
Dias VC; Lucien J; LeGatt DF; Yatscoff RW
Ther Drug Monit; 1995 Feb; 17(1):84-8. PubMed ID: 7725383
[TBL] [Abstract][Full Text] [Related]
42. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
[TBL] [Abstract][Full Text] [Related]
43. Sensitization of human hepatic stellate cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by leflunomide.
Tang X; Yang J; Li J
Biol Pharm Bull; 2009 Jun; 32(6):963-7. PubMed ID: 19483299
[TBL] [Abstract][Full Text] [Related]
44. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC; Dayer JM
Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of porcine epidemic diarrhea virus (PEDV) replication by A77 1726 through targeting JAK and Src tyrosine kinases.
Li X; Sun J; Prinz RA; Liu X; Xu X
Virology; 2020 Dec; 551():75-83. PubMed ID: 32829915
[TBL] [Abstract][Full Text] [Related]
46. Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats.
Silva HT; Shorthouse R; Morris RE
Transplant Proc; 1996 Dec; 28(6):3092-4. PubMed ID: 8962197
[No Abstract] [Full Text] [Related]
47. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
van Roon EN; Jansen TL; van de Laar MA; Janssen M; Yska JP; Keuper R; Houtman PM; Brouwers JR
Ann Rheum Dis; 2005 Apr; 64(4):569-74. PubMed ID: 15345501
[TBL] [Abstract][Full Text] [Related]
48. Suppressive effects of leflunomide on leptin-induced collagen I production involved in hepatic stellate cell proliferation.
Si HF; Li J; Lü XW; Jin Y
Exp Biol Med (Maywood); 2007 Mar; 232(3):427-36. PubMed ID: 17327477
[TBL] [Abstract][Full Text] [Related]
49. Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
Stojic Vukanic Z; Dimitrijevic M; Colic M; Popovic P; Jandric D
Transplant Proc; 2001 May; 33(3):2137-8. PubMed ID: 11377478
[No Abstract] [Full Text] [Related]
50. [The active metabolite of leflunomide A771726 inhibits proliferation and collagen synthesis of hepatic stellate cell].
Yao HW; Li J; Chen JQ; Xu SY
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 33(6):515-8, 528. PubMed ID: 15586409
[TBL] [Abstract][Full Text] [Related]
51. Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs.
Curnock AP; Robson PA; Yea CM; Moss D; Gadher S; Thomson TA; Westwood R; Ruuth E; Williamson RA
J Pharmacol Exp Ther; 1997 Jul; 282(1):339-47. PubMed ID: 9223572
[TBL] [Abstract][Full Text] [Related]
52. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes.
Miljkovic D; Samardzic T; Mostarica Stojkovic M; Stosic-Grujicic S; Popadic D; Trajkovic V
Brain Res; 2001 Jan; 889(1-2):331-8. PubMed ID: 11166726
[TBL] [Abstract][Full Text] [Related]
53. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
Bruneau JM; Yea CM; Spinella-Jaegle S; Fudali C; Woodward K; Robson PA; Sautès C; Westwood R; Kuo EA; Williamson RA; Ruuth E
Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):299-303. PubMed ID: 9820804
[TBL] [Abstract][Full Text] [Related]
54. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.
O'Donnell EF; Kopparapu PR; Koch DC; Jang HS; Phillips JL; Tanguay RL; Kerkvliet NI; Kolluri SK
PLoS One; 2012; 7(7):e40926. PubMed ID: 22815870
[TBL] [Abstract][Full Text] [Related]
55. Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes.
Shi Q; Yang X; Greenhaw J; Salminen WF
Toxicol Sci; 2011 Aug; 122(2):579-86. PubMed ID: 21546349
[TBL] [Abstract][Full Text] [Related]
56. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
Dietrich S; Krämer OH; Hahn E; Schäfer C; Giese T; Hess M; Tretter T; Rieger M; Hüllein J; Zenz T; Ho AD; Dreger P; Luft T
Clin Cancer Res; 2012 Jan; 18(2):417-31. PubMed ID: 22072733
[TBL] [Abstract][Full Text] [Related]
57. Treatment of renal allograft polyoma BK virus infection with leflunomide.
Josephson MA; Gillen D; Javaid B; Kadambi P; Meehan S; Foster P; Harland R; Thistlethwaite RJ; Garfinkel M; Atwood W; Jordan J; Sadhu M; Millis MJ; Williams J
Transplantation; 2006 Mar; 81(5):704-10. PubMed ID: 16534472
[TBL] [Abstract][Full Text] [Related]
58. The active metabolite of leflunomide A771726 inhibits corneal neovascularization.
Zhang M; Hao N; Bian F
J Huazhong Univ Sci Technolog Med Sci; 2008 Jun; 28(3):364-8. PubMed ID: 18563344
[TBL] [Abstract][Full Text] [Related]
59. Post-infection A77-1726 blocks pathophysiologic sequelae of respiratory syncytial virus infection.
Davis IC; Lazarowski ER; Chen FP; Hickman-Davis JM; Sullender WM; Matalon S
Am J Respir Cell Mol Biol; 2007 Oct; 37(4):379-86. PubMed ID: 17541010
[TBL] [Abstract][Full Text] [Related]
60. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay.
Slauson SD; Silva HT; Sherwood SW; Morris RE
Immunol Lett; 1999 Apr; 67(3):179-83. PubMed ID: 10369124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
